nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—CYP1A1—Tretinoin—peripheral nervous system neoplasm	0.0787	0.142	CbGbCtD
Thalidomide—CYP1A1—Dacarbazine—peripheral nervous system neoplasm	0.0677	0.122	CbGbCtD
Thalidomide—CYP2E1—Dacarbazine—peripheral nervous system neoplasm	0.0523	0.0945	CbGbCtD
Thalidomide—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0472	0.0854	CbGbCtD
Thalidomide—PTGS2—Cisplatin—peripheral nervous system neoplasm	0.0399	0.0721	CbGbCtD
Thalidomide—PTGS2—Etoposide—peripheral nervous system neoplasm	0.0392	0.0709	CbGbCtD
Thalidomide—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0378	0.0683	CbGbCtD
Thalidomide—PTGS1—Etoposide—peripheral nervous system neoplasm	0.0331	0.0598	CbGbCtD
Thalidomide—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0317	0.0573	CbGbCtD
Thalidomide—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0302	0.0546	CbGbCtD
Thalidomide—CYP2E1—Etoposide—peripheral nervous system neoplasm	0.0256	0.0462	CbGbCtD
Thalidomide—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.0217	0.0392	CbGbCtD
Thalidomide—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.0199	0.0359	CbGbCtD
Thalidomide—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.0148	0.0267	CbGbCtD
Thalidomide—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.0136	0.0245	CbGbCtD
Thalidomide—Lenalidomide—ABCB1—peripheral nervous system neoplasm	0.00175	0.518	CrCbGaD
Thalidomide—Pomalidomide—ABCB1—peripheral nervous system neoplasm	0.00162	0.482	CrCbGaD
Thalidomide—FGFR2—skull—peripheral nervous system neoplasm	0.000106	0.31	CbGeAlD
Thalidomide—Pneumonia—Epirubicin—peripheral nervous system neoplasm	7.13e-05	0.000216	CcSEcCtD
Thalidomide—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	7.09e-05	0.000215	CcSEcCtD
Thalidomide—Drowsiness—Epirubicin—peripheral nervous system neoplasm	7.09e-05	0.000215	CcSEcCtD
Thalidomide—Infestation—Epirubicin—peripheral nervous system neoplasm	7.09e-05	0.000215	CcSEcCtD
Thalidomide—Vomiting—Dactinomycin—peripheral nervous system neoplasm	7.09e-05	0.000215	CcSEcCtD
Thalidomide—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	7.08e-05	0.000214	CcSEcCtD
Thalidomide—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	7.07e-05	0.000214	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	7.03e-05	0.000213	CcSEcCtD
Thalidomide—Rash—Dactinomycin—peripheral nervous system neoplasm	7.03e-05	0.000213	CcSEcCtD
Thalidomide—Decreased appetite—Etoposide—peripheral nervous system neoplasm	7.01e-05	0.000212	CcSEcCtD
Thalidomide—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	6.99e-05	0.000212	CcSEcCtD
Thalidomide—Renal failure—Epirubicin—peripheral nervous system neoplasm	6.97e-05	0.000211	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	6.96e-05	0.000211	CcSEcCtD
Thalidomide—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	6.96e-05	0.000211	CcSEcCtD
Thalidomide—Fatigue—Etoposide—peripheral nervous system neoplasm	6.95e-05	0.000211	CcSEcCtD
Thalidomide—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	6.95e-05	0.000211	CcSEcCtD
Thalidomide—Stomatitis—Epirubicin—peripheral nervous system neoplasm	6.91e-05	0.000209	CcSEcCtD
Thalidomide—Constipation—Etoposide—peripheral nervous system neoplasm	6.9e-05	0.000209	CcSEcCtD
Thalidomide—Pain—Etoposide—peripheral nervous system neoplasm	6.9e-05	0.000209	CcSEcCtD
Thalidomide—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	6.89e-05	0.000209	CcSEcCtD
Thalidomide—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	6.88e-05	0.000208	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	6.84e-05	0.000207	CcSEcCtD
Thalidomide—Dizziness—Alitretinoin—peripheral nervous system neoplasm	6.83e-05	0.000207	CcSEcCtD
Thalidomide—Diarrhoea—Vincristine—peripheral nervous system neoplasm	6.81e-05	0.000206	CcSEcCtD
Thalidomide—Sweating—Epirubicin—peripheral nervous system neoplasm	6.8e-05	0.000206	CcSEcCtD
Thalidomide—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	6.8e-05	0.000206	CcSEcCtD
Thalidomide—Haematuria—Epirubicin—peripheral nervous system neoplasm	6.76e-05	0.000205	CcSEcCtD
Thalidomide—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	6.72e-05	0.000203	CcSEcCtD
Thalidomide—Weight increased—Doxorubicin—peripheral nervous system neoplasm	6.7e-05	0.000203	CcSEcCtD
Thalidomide—Epistaxis—Epirubicin—peripheral nervous system neoplasm	6.69e-05	0.000203	CcSEcCtD
Thalidomide—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	6.66e-05	0.000202	CcSEcCtD
Thalidomide—Sinusitis—Epirubicin—peripheral nervous system neoplasm	6.65e-05	0.000201	CcSEcCtD
Thalidomide—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	6.65e-05	0.000201	CcSEcCtD
Thalidomide—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	6.64e-05	0.000201	CcSEcCtD
Thalidomide—Nausea—Dactinomycin—peripheral nervous system neoplasm	6.62e-05	0.000201	CcSEcCtD
Thalidomide—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	6.62e-05	0.0002	CcSEcCtD
Thalidomide—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	6.6e-05	0.0002	CcSEcCtD
Thalidomide—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	6.6e-05	0.0002	CcSEcCtD
Thalidomide—Dizziness—Vincristine—peripheral nervous system neoplasm	6.58e-05	0.000199	CcSEcCtD
Thalidomide—Vomiting—Alitretinoin—peripheral nervous system neoplasm	6.57e-05	0.000199	CcSEcCtD
Thalidomide—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	6.56e-05	0.000199	CcSEcCtD
Thalidomide—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	6.56e-05	0.000199	CcSEcCtD
Thalidomide—Infestation—Doxorubicin—peripheral nervous system neoplasm	6.56e-05	0.000199	CcSEcCtD
Thalidomide—Rash—Alitretinoin—peripheral nervous system neoplasm	6.52e-05	0.000197	CcSEcCtD
Thalidomide—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	6.51e-05	0.000197	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	6.5e-05	0.000197	CcSEcCtD
Thalidomide—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	6.49e-05	0.000197	CcSEcCtD
Thalidomide—Bradycardia—Epirubicin—peripheral nervous system neoplasm	6.48e-05	0.000196	CcSEcCtD
Thalidomide—Headache—Alitretinoin—peripheral nervous system neoplasm	6.47e-05	0.000196	CcSEcCtD
Thalidomide—Renal failure—Doxorubicin—peripheral nervous system neoplasm	6.45e-05	0.000195	CcSEcCtD
Thalidomide—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	6.43e-05	0.000195	CcSEcCtD
Thalidomide—Urticaria—Etoposide—peripheral nervous system neoplasm	6.41e-05	0.000194	CcSEcCtD
Thalidomide—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	6.39e-05	0.000194	CcSEcCtD
Thalidomide—Rhinitis—Epirubicin—peripheral nervous system neoplasm	6.38e-05	0.000193	CcSEcCtD
Thalidomide—Abdominal pain—Etoposide—peripheral nervous system neoplasm	6.38e-05	0.000193	CcSEcCtD
Thalidomide—Body temperature increased—Etoposide—peripheral nervous system neoplasm	6.38e-05	0.000193	CcSEcCtD
Thalidomide—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	6.38e-05	0.000193	CcSEcCtD
Thalidomide—Hepatitis—Epirubicin—peripheral nervous system neoplasm	6.36e-05	0.000193	CcSEcCtD
Thalidomide—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	6.33e-05	0.000192	CcSEcCtD
Thalidomide—Vomiting—Vincristine—peripheral nervous system neoplasm	6.33e-05	0.000192	CcSEcCtD
Thalidomide—Asthenia—Cisplatin—peripheral nervous system neoplasm	6.32e-05	0.000191	CcSEcCtD
Thalidomide—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	6.32e-05	0.000191	CcSEcCtD
Thalidomide—Sweating—Doxorubicin—peripheral nervous system neoplasm	6.29e-05	0.000191	CcSEcCtD
Thalidomide—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	6.29e-05	0.00019	CcSEcCtD
Thalidomide—Rash—Vincristine—peripheral nervous system neoplasm	6.28e-05	0.00019	CcSEcCtD
Thalidomide—Dermatitis—Vincristine—peripheral nervous system neoplasm	6.27e-05	0.00019	CcSEcCtD
Thalidomide—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	6.27e-05	0.00019	CcSEcCtD
Thalidomide—Haematuria—Doxorubicin—peripheral nervous system neoplasm	6.25e-05	0.000189	CcSEcCtD
Thalidomide—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	6.24e-05	0.000189	CcSEcCtD
Thalidomide—Headache—Vincristine—peripheral nervous system neoplasm	6.24e-05	0.000189	CcSEcCtD
Thalidomide—TNF—MAPK Signaling Pathway—MYC—peripheral nervous system neoplasm	6.23e-05	0.000552	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—HRAS—peripheral nervous system neoplasm	6.21e-05	0.00055	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—TP53—peripheral nervous system neoplasm	6.19e-05	0.000548	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—AKT1—peripheral nervous system neoplasm	6.19e-05	0.000548	CbGpPWpGaD
Thalidomide—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	6.19e-05	0.000187	CcSEcCtD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	6.17e-05	0.000547	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—PTPN11—peripheral nervous system neoplasm	6.16e-05	0.000546	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	6.16e-05	0.000546	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ENO2—peripheral nervous system neoplasm	6.16e-05	0.000546	CbGpPWpGaD
Thalidomide—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	6.15e-05	0.000186	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	6.14e-05	0.000544	CbGpPWpGaD
Thalidomide—Nausea—Alitretinoin—peripheral nervous system neoplasm	6.14e-05	0.000186	CcSEcCtD
Thalidomide—Visual impairment—Epirubicin—peripheral nervous system neoplasm	6.13e-05	0.000186	CcSEcCtD
Thalidomide—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	6.12e-05	0.000185	CcSEcCtD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—HRAS—peripheral nervous system neoplasm	6.12e-05	0.000542	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	6.12e-05	0.000542	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	6.06e-05	0.000537	CbGpPWpGaD
Thalidomide—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	6.02e-05	0.000182	CcSEcCtD
Thalidomide—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	6.02e-05	0.000182	CcSEcCtD
Thalidomide—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	5.99e-05	0.000182	CcSEcCtD
Thalidomide—Eye disorder—Epirubicin—peripheral nervous system neoplasm	5.95e-05	0.00018	CcSEcCtD
Thalidomide—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	5.94e-05	0.00018	CcSEcCtD
Thalidomide—Tinnitus—Epirubicin—peripheral nervous system neoplasm	5.93e-05	0.00018	CcSEcCtD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—AKT1—peripheral nervous system neoplasm	5.92e-05	0.000525	CbGpPWpGaD
Thalidomide—Nausea—Vincristine—peripheral nervous system neoplasm	5.91e-05	0.000179	CcSEcCtD
Thalidomide—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	5.91e-05	0.000179	CcSEcCtD
Thalidomide—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	5.9e-05	0.000179	CcSEcCtD
Thalidomide—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	5.89e-05	0.000178	CcSEcCtD
Thalidomide—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	5.86e-05	0.000177	CcSEcCtD
Thalidomide—PTGS2—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.85e-05	0.000518	CbGpPWpGaD
Thalidomide—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	5.84e-05	0.000177	CcSEcCtD
Thalidomide—FGFR2—Signaling by FGFR in disease—HRAS—peripheral nervous system neoplasm	5.84e-05	0.000518	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	5.84e-05	0.000518	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—HRAS—peripheral nervous system neoplasm	5.84e-05	0.000518	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—NRAS—peripheral nervous system neoplasm	5.83e-05	0.000517	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	5.83e-05	0.000516	CbGpPWpGaD
Thalidomide—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	5.82e-05	0.000176	CcSEcCtD
Thalidomide—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	5.8e-05	0.000176	CcSEcCtD
Thalidomide—FGFR2—Signaling by EGFR—HRAS—peripheral nervous system neoplasm	5.79e-05	0.000513	CbGpPWpGaD
Thalidomide—Asthenia—Etoposide—peripheral nervous system neoplasm	5.79e-05	0.000175	CcSEcCtD
Thalidomide—Angiopathy—Epirubicin—peripheral nervous system neoplasm	5.77e-05	0.000175	CcSEcCtD
Thalidomide—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	5.77e-05	0.000175	CcSEcCtD
Thalidomide—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	5.75e-05	0.000174	CcSEcCtD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	5.74e-05	0.000509	CbGpPWpGaD
Thalidomide—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	5.74e-05	0.000174	CcSEcCtD
Thalidomide—NFKB1—Signaling by NGF—NRAS—peripheral nervous system neoplasm	5.73e-05	0.000508	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	5.73e-05	0.000508	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	5.71e-05	0.000506	CbGpPWpGaD
Thalidomide—Chills—Epirubicin—peripheral nervous system neoplasm	5.71e-05	0.000173	CcSEcCtD
Thalidomide—Pruritus—Etoposide—peripheral nervous system neoplasm	5.71e-05	0.000173	CcSEcCtD
Thalidomide—NFKB1—B Cell Activation—HRAS—peripheral nervous system neoplasm	5.7e-05	0.000505	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—AKT1—peripheral nervous system neoplasm	5.7e-05	0.000505	CbGpPWpGaD
Thalidomide—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	5.69e-05	0.000172	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—VIP—peripheral nervous system neoplasm	5.68e-05	0.000504	CbGpPWpGaD
Thalidomide—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	5.67e-05	0.000172	CcSEcCtD
Thalidomide—NFKB1—MAPK Signaling Pathway—AKT1—peripheral nervous system neoplasm	5.67e-05	0.000502	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFNB1—peripheral nervous system neoplasm	5.62e-05	0.000498	CbGpPWpGaD
Thalidomide—Alopecia—Epirubicin—peripheral nervous system neoplasm	5.62e-05	0.00017	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	5.62e-05	0.000498	CbGpPWpGaD
Thalidomide—Vomiting—Cisplatin—peripheral nervous system neoplasm	5.6e-05	0.00017	CcSEcCtD
Thalidomide—Mental disorder—Epirubicin—peripheral nervous system neoplasm	5.58e-05	0.000169	CcSEcCtD
Thalidomide—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	5.57e-05	0.000169	CcSEcCtD
Thalidomide—FGFR2—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	5.57e-05	0.000493	CbGpPWpGaD
Thalidomide—Rash—Cisplatin—peripheral nervous system neoplasm	5.55e-05	0.000168	CcSEcCtD
Thalidomide—Dermatitis—Cisplatin—peripheral nervous system neoplasm	5.55e-05	0.000168	CcSEcCtD
Thalidomide—Malnutrition—Epirubicin—peripheral nervous system neoplasm	5.54e-05	0.000168	CcSEcCtD
Thalidomide—FGFR2—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	5.54e-05	0.000491	CbGpPWpGaD
Thalidomide—Diarrhoea—Etoposide—peripheral nervous system neoplasm	5.52e-05	0.000167	CcSEcCtD
Thalidomide—FGFR2—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	5.51e-05	0.000488	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.5e-05	0.000488	CbGpPWpGaD
Thalidomide—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	5.5e-05	0.000167	CcSEcCtD
Thalidomide—CYP3A5—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.49e-05	0.000487	CbGpPWpGaD
Thalidomide—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	5.49e-05	0.000166	CcSEcCtD
Thalidomide—FGFR2—DAP12 signaling—AKT1—peripheral nervous system neoplasm	5.48e-05	0.000486	CbGpPWpGaD
Thalidomide—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	5.47e-05	0.000166	CcSEcCtD
Thalidomide—Flatulence—Epirubicin—peripheral nervous system neoplasm	5.46e-05	0.000165	CcSEcCtD
Thalidomide—TNF—Apoptosis—TP53—peripheral nervous system neoplasm	5.46e-05	0.000483	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—NRAS—peripheral nervous system neoplasm	5.44e-05	0.000482	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—PTPN11—peripheral nervous system neoplasm	5.44e-05	0.000482	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	5.44e-05	0.000482	CbGpPWpGaD
Thalidomide—Tension—Epirubicin—peripheral nervous system neoplasm	5.44e-05	0.000165	CcSEcCtD
Thalidomide—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	5.43e-05	0.000164	CcSEcCtD
Thalidomide—FGFR2—B Cell Activation—HRAS—peripheral nervous system neoplasm	5.41e-05	0.000479	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—AKT1—peripheral nervous system neoplasm	5.4e-05	0.000479	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VIP—peripheral nervous system neoplasm	5.39e-05	0.000478	CbGpPWpGaD
Thalidomide—Nervousness—Epirubicin—peripheral nervous system neoplasm	5.38e-05	0.000163	CcSEcCtD
Thalidomide—Back pain—Epirubicin—peripheral nervous system neoplasm	5.36e-05	0.000162	CcSEcCtD
Thalidomide—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	5.34e-05	0.000162	CcSEcCtD
Thalidomide—FGFR2—Immune System—IFNB1—peripheral nervous system neoplasm	5.34e-05	0.000473	CbGpPWpGaD
Thalidomide—Dizziness—Etoposide—peripheral nervous system neoplasm	5.33e-05	0.000162	CcSEcCtD
Thalidomide—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	5.33e-05	0.000161	CcSEcCtD
Thalidomide—PTGS1—Metabolism—GNS—peripheral nervous system neoplasm	5.32e-05	0.000472	CbGpPWpGaD
Thalidomide—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	5.32e-05	0.000161	CcSEcCtD
Thalidomide—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	5.31e-05	0.000161	CcSEcCtD
Thalidomide—Chills—Doxorubicin—peripheral nervous system neoplasm	5.28e-05	0.00016	CcSEcCtD
Thalidomide—PTGS2—C-MYB transcription factor network—HRAS—peripheral nervous system neoplasm	5.27e-05	0.000467	CbGpPWpGaD
Thalidomide—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	5.26e-05	0.000159	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.25e-05	0.000465	CbGpPWpGaD
Thalidomide—Nausea—Cisplatin—peripheral nervous system neoplasm	5.23e-05	0.000158	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	5.22e-05	0.000463	CbGpPWpGaD
Thalidomide—Vision blurred—Epirubicin—peripheral nervous system neoplasm	5.22e-05	0.000158	CcSEcCtD
Thalidomide—Alopecia—Doxorubicin—peripheral nervous system neoplasm	5.2e-05	0.000158	CcSEcCtD
Thalidomide—CYP1A1—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.19e-05	0.00046	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	5.18e-05	0.000459	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—PTPN11—peripheral nervous system neoplasm	5.16e-05	0.000457	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—AKT1—peripheral nervous system neoplasm	5.16e-05	0.000457	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	5.16e-05	0.000457	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	5.16e-05	0.000457	CbGpPWpGaD
Thalidomide—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	5.16e-05	0.000156	CcSEcCtD
Thalidomide—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	5.14e-05	0.000156	CcSEcCtD
Thalidomide—Vomiting—Etoposide—peripheral nervous system neoplasm	5.13e-05	0.000155	CcSEcCtD
Thalidomide—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	5.13e-05	0.000155	CcSEcCtD
Thalidomide—Anaemia—Epirubicin—peripheral nervous system neoplasm	5.12e-05	0.000155	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	5.12e-05	0.000453	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—peripheral nervous system neoplasm	5.11e-05	0.000453	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	5.11e-05	0.000453	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—MYC—peripheral nervous system neoplasm	5.11e-05	0.000453	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NME1—peripheral nervous system neoplasm	5.11e-05	0.000452	CbGpPWpGaD
Thalidomide—Agitation—Epirubicin—peripheral nervous system neoplasm	5.09e-05	0.000154	CcSEcCtD
Thalidomide—Rash—Etoposide—peripheral nervous system neoplasm	5.09e-05	0.000154	CcSEcCtD
Thalidomide—Dermatitis—Etoposide—peripheral nervous system neoplasm	5.08e-05	0.000154	CcSEcCtD
Thalidomide—TNF—Developmental Biology—MET—peripheral nervous system neoplasm	5.07e-05	0.00045	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	5.07e-05	0.000449	CbGpPWpGaD
Thalidomide—Headache—Etoposide—peripheral nervous system neoplasm	5.05e-05	0.000153	CcSEcCtD
Thalidomide—Flatulence—Doxorubicin—peripheral nervous system neoplasm	5.05e-05	0.000153	CcSEcCtD
Thalidomide—PTGS2—Disease—GNS—peripheral nervous system neoplasm	5.05e-05	0.000447	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	5.05e-05	0.000447	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—AKT1—peripheral nervous system neoplasm	5.03e-05	0.000446	CbGpPWpGaD
Thalidomide—Tension—Doxorubicin—peripheral nervous system neoplasm	5.03e-05	0.000152	CcSEcCtD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—AKT1—peripheral nervous system neoplasm	5.03e-05	0.000445	CbGpPWpGaD
Thalidomide—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	5.02e-05	0.000152	CcSEcCtD
Thalidomide—Malaise—Epirubicin—peripheral nervous system neoplasm	5e-05	0.000151	CcSEcCtD
Thalidomide—Nervousness—Doxorubicin—peripheral nervous system neoplasm	4.98e-05	0.000151	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	4.98e-05	0.000441	CbGpPWpGaD
Thalidomide—Vertigo—Epirubicin—peripheral nervous system neoplasm	4.98e-05	0.000151	CcSEcCtD
Thalidomide—Syncope—Epirubicin—peripheral nervous system neoplasm	4.97e-05	0.000151	CcSEcCtD
Thalidomide—FGFR2—Disease—SLC2A1—peripheral nervous system neoplasm	4.96e-05	0.00044	CbGpPWpGaD
Thalidomide—Leukopenia—Epirubicin—peripheral nervous system neoplasm	4.96e-05	0.00015	CcSEcCtD
Thalidomide—Back pain—Doxorubicin—peripheral nervous system neoplasm	4.96e-05	0.00015	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	4.96e-05	0.000439	CbGpPWpGaD
Thalidomide—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	4.93e-05	0.000149	CcSEcCtD
Thalidomide—PTGS1—Metabolism—COX2—peripheral nervous system neoplasm	4.91e-05	0.000435	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	4.91e-05	0.000435	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	4.9e-05	0.000434	CbGpPWpGaD
Thalidomide—Palpitations—Epirubicin—peripheral nervous system neoplasm	4.9e-05	0.000148	CcSEcCtD
Thalidomide—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	4.87e-05	0.000148	CcSEcCtD
Thalidomide—NFKB1—Developmental Biology—ERBB2—peripheral nervous system neoplasm	4.87e-05	0.000431	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	4.86e-05	0.000431	CbGpPWpGaD
Thalidomide—Cough—Epirubicin—peripheral nervous system neoplasm	4.83e-05	0.000146	CcSEcCtD
Thalidomide—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	4.83e-05	0.000146	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	4.83e-05	0.000428	CbGpPWpGaD
Thalidomide—Convulsion—Epirubicin—peripheral nervous system neoplasm	4.8e-05	0.000145	CcSEcCtD
Thalidomide—Nausea—Etoposide—peripheral nervous system neoplasm	4.79e-05	0.000145	CcSEcCtD
Thalidomide—Hypertension—Epirubicin—peripheral nervous system neoplasm	4.78e-05	0.000145	CcSEcCtD
Thalidomide—FGFR2—B Cell Activation—AKT1—peripheral nervous system neoplasm	4.77e-05	0.000423	CbGpPWpGaD
Thalidomide—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	4.76e-05	0.000144	CcSEcCtD
Thalidomide—Anaemia—Doxorubicin—peripheral nervous system neoplasm	4.74e-05	0.000144	CcSEcCtD
Thalidomide—Myalgia—Epirubicin—peripheral nervous system neoplasm	4.72e-05	0.000143	CcSEcCtD
Thalidomide—Chest pain—Epirubicin—peripheral nervous system neoplasm	4.72e-05	0.000143	CcSEcCtD
Thalidomide—Arthralgia—Epirubicin—peripheral nervous system neoplasm	4.72e-05	0.000143	CcSEcCtD
Thalidomide—Agitation—Doxorubicin—peripheral nervous system neoplasm	4.71e-05	0.000143	CcSEcCtD
Thalidomide—Anxiety—Epirubicin—peripheral nervous system neoplasm	4.7e-05	0.000142	CcSEcCtD
Thalidomide—TNF—Developmental Biology—PTPN11—peripheral nervous system neoplasm	4.69e-05	0.000416	CbGpPWpGaD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	4.68e-05	0.000142	CcSEcCtD
Thalidomide—NFKB1—Cellular responses to stress—TP53—peripheral nervous system neoplasm	4.68e-05	0.000414	CbGpPWpGaD
Thalidomide—Discomfort—Epirubicin—peripheral nervous system neoplasm	4.66e-05	0.000141	CcSEcCtD
Thalidomide—Malaise—Doxorubicin—peripheral nervous system neoplasm	4.62e-05	0.00014	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	4.62e-05	0.000409	CbGpPWpGaD
Thalidomide—Dry mouth—Epirubicin—peripheral nervous system neoplasm	4.61e-05	0.00014	CcSEcCtD
Thalidomide—TNF—Apoptosis—AKT1—peripheral nervous system neoplasm	4.61e-05	0.000408	CbGpPWpGaD
Thalidomide—Vertigo—Doxorubicin—peripheral nervous system neoplasm	4.61e-05	0.00014	CcSEcCtD
Thalidomide—Syncope—Doxorubicin—peripheral nervous system neoplasm	4.6e-05	0.000139	CcSEcCtD
Thalidomide—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	4.59e-05	0.000139	CcSEcCtD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	4.57e-05	0.000405	CbGpPWpGaD
Thalidomide—Confusional state—Epirubicin—peripheral nervous system neoplasm	4.56e-05	0.000138	CcSEcCtD
Thalidomide—Palpitations—Doxorubicin—peripheral nervous system neoplasm	4.53e-05	0.000137	CcSEcCtD
Thalidomide—Oedema—Epirubicin—peripheral nervous system neoplasm	4.52e-05	0.000137	CcSEcCtD
Thalidomide—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	4.51e-05	0.000136	CcSEcCtD
Thalidomide—Infection—Epirubicin—peripheral nervous system neoplasm	4.49e-05	0.000136	CcSEcCtD
Thalidomide—Cough—Doxorubicin—peripheral nervous system neoplasm	4.47e-05	0.000136	CcSEcCtD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	4.45e-05	0.000395	CbGpPWpGaD
Thalidomide—Shock—Epirubicin—peripheral nervous system neoplasm	4.45e-05	0.000135	CcSEcCtD
Thalidomide—Convulsion—Doxorubicin—peripheral nervous system neoplasm	4.44e-05	0.000135	CcSEcCtD
Thalidomide—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	4.43e-05	0.000134	CcSEcCtD
Thalidomide—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	4.43e-05	0.000134	CcSEcCtD
Thalidomide—Hypertension—Doxorubicin—peripheral nervous system neoplasm	4.43e-05	0.000134	CcSEcCtD
Thalidomide—Tachycardia—Epirubicin—peripheral nervous system neoplasm	4.41e-05	0.000134	CcSEcCtD
Thalidomide—Skin disorder—Epirubicin—peripheral nervous system neoplasm	4.39e-05	0.000133	CcSEcCtD
Thalidomide—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	4.37e-05	0.000132	CcSEcCtD
Thalidomide—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	4.36e-05	0.000132	CcSEcCtD
Thalidomide—Myalgia—Doxorubicin—peripheral nervous system neoplasm	4.36e-05	0.000132	CcSEcCtD
Thalidomide—Chest pain—Doxorubicin—peripheral nervous system neoplasm	4.36e-05	0.000132	CcSEcCtD
Thalidomide—Anxiety—Doxorubicin—peripheral nervous system neoplasm	4.35e-05	0.000132	CcSEcCtD
Thalidomide—NFKB1—Immune System—HGF—peripheral nervous system neoplasm	4.34e-05	0.000385	CbGpPWpGaD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	4.33e-05	0.000131	CcSEcCtD
Thalidomide—TNF—MAPK Signaling Pathway—AKT1—peripheral nervous system neoplasm	4.32e-05	0.000383	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	4.31e-05	0.000382	CbGpPWpGaD
Thalidomide—Discomfort—Doxorubicin—peripheral nervous system neoplasm	4.31e-05	0.000131	CcSEcCtD
Thalidomide—Anorexia—Epirubicin—peripheral nervous system neoplasm	4.31e-05	0.000131	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—ERBB2—peripheral nervous system neoplasm	4.3e-05	0.000381	CbGpPWpGaD
Thalidomide—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	4.27e-05	0.000129	CcSEcCtD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HRAS—peripheral nervous system neoplasm	4.27e-05	0.000378	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.25e-05	0.000376	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GNS—peripheral nervous system neoplasm	4.23e-05	0.000375	CbGpPWpGaD
Thalidomide—Hypotension—Epirubicin—peripheral nervous system neoplasm	4.22e-05	0.000128	CcSEcCtD
Thalidomide—Confusional state—Doxorubicin—peripheral nervous system neoplasm	4.22e-05	0.000128	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—peripheral nervous system neoplasm	4.2e-05	0.000372	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—HRAS—peripheral nervous system neoplasm	4.19e-05	0.000372	CbGpPWpGaD
Thalidomide—Oedema—Doxorubicin—peripheral nervous system neoplasm	4.18e-05	0.000127	CcSEcCtD
Thalidomide—Infection—Doxorubicin—peripheral nervous system neoplasm	4.16e-05	0.000126	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	4.13e-05	0.000366	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HGF—peripheral nervous system neoplasm	4.12e-05	0.000365	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	4.12e-05	0.000125	CcSEcCtD
Thalidomide—Shock—Doxorubicin—peripheral nervous system neoplasm	4.12e-05	0.000125	CcSEcCtD
Thalidomide—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	4.1e-05	0.000124	CcSEcCtD
Thalidomide—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	4.1e-05	0.000124	CcSEcCtD
Thalidomide—Insomnia—Epirubicin—peripheral nervous system neoplasm	4.09e-05	0.000124	CcSEcCtD
Thalidomide—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	4.08e-05	0.000124	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—ERBB2—peripheral nervous system neoplasm	4.08e-05	0.000361	CbGpPWpGaD
Thalidomide—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	4.06e-05	0.000123	CcSEcCtD
Thalidomide—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	4.06e-05	0.000123	CcSEcCtD
Thalidomide—PTGS2—Metabolism—NME1—peripheral nervous system neoplasm	4.05e-05	0.000359	CbGpPWpGaD
Thalidomide—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	4.04e-05	0.000123	CcSEcCtD
Thalidomide—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	4.03e-05	0.000122	CcSEcCtD
Thalidomide—Somnolence—Epirubicin—peripheral nervous system neoplasm	4.02e-05	0.000122	CcSEcCtD
Thalidomide—Anorexia—Doxorubicin—peripheral nervous system neoplasm	3.99e-05	0.000121	CcSEcCtD
Thalidomide—FGFR2—Signaling by NGF—HRAS—peripheral nervous system neoplasm	3.98e-05	0.000353	CbGpPWpGaD
Thalidomide—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	3.98e-05	0.000121	CcSEcCtD
Thalidomide—CYP2E1—Metabolism—GNS—peripheral nervous system neoplasm	3.98e-05	0.000353	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GNS—peripheral nervous system neoplasm	3.97e-05	0.000352	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.94e-05	0.000349	CbGpPWpGaD
Thalidomide—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	3.93e-05	0.000119	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	3.92e-05	0.000347	CbGpPWpGaD
Thalidomide—Hypotension—Doxorubicin—peripheral nervous system neoplasm	3.91e-05	0.000118	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	3.9e-05	0.000118	CcSEcCtD
Thalidomide—PTGS2—Metabolism—COX2—peripheral nervous system neoplasm	3.9e-05	0.000346	CbGpPWpGaD
Thalidomide—Fatigue—Epirubicin—peripheral nervous system neoplasm	3.9e-05	0.000118	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	3.9e-05	0.000345	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.87e-05	0.000343	CbGpPWpGaD
Thalidomide—Pain—Epirubicin—peripheral nervous system neoplasm	3.87e-05	0.000117	CcSEcCtD
Thalidomide—Constipation—Epirubicin—peripheral nervous system neoplasm	3.87e-05	0.000117	CcSEcCtD
Thalidomide—CYP2E1—Metabolism—NME1—peripheral nervous system neoplasm	3.82e-05	0.000338	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	3.81e-05	0.000115	CcSEcCtD
Thalidomide—CYP3A5—Metabolism—NME1—peripheral nervous system neoplasm	3.81e-05	0.000337	CbGpPWpGaD
Thalidomide—Insomnia—Doxorubicin—peripheral nervous system neoplasm	3.78e-05	0.000115	CcSEcCtD
Thalidomide—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	3.76e-05	0.000114	CcSEcCtD
Thalidomide—CYP1A1—Metabolism—GNS—peripheral nervous system neoplasm	3.75e-05	0.000332	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.74e-05	0.000331	CbGpPWpGaD
Thalidomide—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	3.73e-05	0.000113	CcSEcCtD
Thalidomide—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	3.73e-05	0.000113	CcSEcCtD
Thalidomide—Somnolence—Doxorubicin—peripheral nervous system neoplasm	3.72e-05	0.000113	CcSEcCtD
Thalidomide—TNF—Developmental Biology—ERBB2—peripheral nervous system neoplasm	3.71e-05	0.000329	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—AKT1—peripheral nervous system neoplasm	3.7e-05	0.000328	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—NRAS—peripheral nervous system neoplasm	3.7e-05	0.000328	CbGpPWpGaD
Thalidomide—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	3.7e-05	0.000112	CcSEcCtD
Thalidomide—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	3.68e-05	0.000112	CcSEcCtD
Thalidomide—CYP2E1—Metabolism—COX2—peripheral nervous system neoplasm	3.67e-05	0.000325	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—COX2—peripheral nervous system neoplasm	3.66e-05	0.000325	CbGpPWpGaD
Thalidomide—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	3.64e-05	0.00011	CcSEcCtD
Thalidomide—NFKB1—trigeminal ganglion—peripheral nervous system neoplasm	3.62e-05	0.105	CbGeAlD
Thalidomide—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	3.61e-05	0.000109	CcSEcCtD
Thalidomide—Fatigue—Doxorubicin—peripheral nervous system neoplasm	3.61e-05	0.000109	CcSEcCtD
Thalidomide—CYP1A1—Metabolism—NME1—peripheral nervous system neoplasm	3.6e-05	0.000319	CbGpPWpGaD
Thalidomide—Urticaria—Epirubicin—peripheral nervous system neoplasm	3.59e-05	0.000109	CcSEcCtD
Thalidomide—Constipation—Doxorubicin—peripheral nervous system neoplasm	3.58e-05	0.000108	CcSEcCtD
Thalidomide—Pain—Doxorubicin—peripheral nervous system neoplasm	3.58e-05	0.000108	CcSEcCtD
Thalidomide—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	3.57e-05	0.000108	CcSEcCtD
Thalidomide—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	3.57e-05	0.000108	CcSEcCtD
Thalidomide—PTGS2—Disease—PPP3R1—peripheral nervous system neoplasm	3.53e-05	0.000313	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	3.53e-05	0.000313	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—AKT1—peripheral nervous system neoplasm	3.51e-05	0.000311	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	3.48e-05	0.000308	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—COX2—peripheral nervous system neoplasm	3.46e-05	0.000307	CbGpPWpGaD
Thalidomide—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	3.45e-05	0.000104	CcSEcCtD
Thalidomide—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	3.42e-05	0.000104	CcSEcCtD
Thalidomide—NFKB1—parotid gland—peripheral nervous system neoplasm	3.41e-05	0.0995	CbGeAlD
Thalidomide—NFKB1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.37e-05	0.000299	CbGpPWpGaD
Thalidomide—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	3.33e-05	0.000101	CcSEcCtD
Thalidomide—Urticaria—Doxorubicin—peripheral nervous system neoplasm	3.32e-05	0.000101	CcSEcCtD
Thalidomide—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.31e-05	0.000293	CbGpPWpGaD
Thalidomide—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	3.31e-05	0.0001	CcSEcCtD
Thalidomide—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	3.31e-05	0.0001	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—NRAS—peripheral nervous system neoplasm	3.27e-05	0.00029	CbGpPWpGaD
Thalidomide—Asthenia—Epirubicin—peripheral nervous system neoplasm	3.24e-05	9.83e-05	CcSEcCtD
Thalidomide—PTGS1—Metabolism—ENO2—peripheral nervous system neoplasm	3.23e-05	0.000286	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	3.22e-05	0.000285	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.21e-05	0.000285	CbGpPWpGaD
Thalidomide—Pruritus—Epirubicin—peripheral nervous system neoplasm	3.2e-05	9.69e-05	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.2e-05	0.000283	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PTPN11—peripheral nervous system neoplasm	3.17e-05	0.000281	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	3.14e-05	0.000278	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—NRAS—peripheral nervous system neoplasm	3.1e-05	0.000275	CbGpPWpGaD
Thalidomide—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	3.09e-05	9.37e-05	CcSEcCtD
Thalidomide—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	3.08e-05	9.34e-05	CcSEcCtD
Thalidomide—CYP2C19—Metabolism—GNS—peripheral nervous system neoplasm	3.07e-05	0.000272	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ENO2—peripheral nervous system neoplasm	3.06e-05	0.000271	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.05e-05	0.00027	CbGpPWpGaD
Thalidomide—CRBN—trigeminal ganglion—peripheral nervous system neoplasm	3.03e-05	0.0884	CbGeAlD
Thalidomide—FGFR2—Immune System—PTPN11—peripheral nervous system neoplasm	3.01e-05	0.000266	CbGpPWpGaD
Thalidomide—Asthenia—Doxorubicin—peripheral nervous system neoplasm	3e-05	9.09e-05	CcSEcCtD
Thalidomide—Dizziness—Epirubicin—peripheral nervous system neoplasm	2.99e-05	9.06e-05	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	2.98e-05	0.000264	CbGpPWpGaD
Thalidomide—Pruritus—Doxorubicin—peripheral nervous system neoplasm	2.96e-05	8.97e-05	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.95e-05	0.000261	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NME1—peripheral nervous system neoplasm	2.94e-05	0.000261	CbGpPWpGaD
Thalidomide—Vomiting—Epirubicin—peripheral nervous system neoplasm	2.87e-05	8.71e-05	CcSEcCtD
Thalidomide—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	2.86e-05	8.67e-05	CcSEcCtD
Thalidomide—CRBN—parotid gland—peripheral nervous system neoplasm	2.86e-05	0.0834	CbGeAlD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	2.85e-05	0.000253	CbGpPWpGaD
Thalidomide—Rash—Epirubicin—peripheral nervous system neoplasm	2.85e-05	8.64e-05	CcSEcCtD
Thalidomide—Dermatitis—Epirubicin—peripheral nervous system neoplasm	2.85e-05	8.63e-05	CcSEcCtD
Thalidomide—CYP2C19—Metabolism—COX2—peripheral nervous system neoplasm	2.83e-05	0.000251	CbGpPWpGaD
Thalidomide—Headache—Epirubicin—peripheral nervous system neoplasm	2.83e-05	8.58e-05	CcSEcCtD
Thalidomide—TNF—Developmental Biology—NRAS—peripheral nervous system neoplasm	2.82e-05	0.00025	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	2.8e-05	0.000248	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.8e-05	0.000248	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTPN11—peripheral nervous system neoplasm	2.78e-05	0.000246	CbGpPWpGaD
Thalidomide—Dizziness—Doxorubicin—peripheral nervous system neoplasm	2.77e-05	8.38e-05	CcSEcCtD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	2.75e-05	0.000244	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—BCHE—peripheral nervous system neoplasm	2.73e-05	0.000242	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—HRAS—peripheral nervous system neoplasm	2.71e-05	0.00024	CbGpPWpGaD
Thalidomide—Nausea—Epirubicin—peripheral nervous system neoplasm	2.69e-05	8.14e-05	CcSEcCtD
Thalidomide—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	2.68e-05	0.000238	CbGpPWpGaD
Thalidomide—Vomiting—Doxorubicin—peripheral nervous system neoplasm	2.66e-05	8.06e-05	CcSEcCtD
Thalidomide—Rash—Doxorubicin—peripheral nervous system neoplasm	2.64e-05	7.99e-05	CcSEcCtD
Thalidomide—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	2.64e-05	7.98e-05	CcSEcCtD
Thalidomide—Headache—Doxorubicin—peripheral nervous system neoplasm	2.62e-05	7.94e-05	CcSEcCtD
Thalidomide—PTGS1—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.6e-05	0.00023	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	2.58e-05	0.000229	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TH—peripheral nervous system neoplasm	2.56e-05	0.000227	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ENO2—peripheral nervous system neoplasm	2.56e-05	0.000227	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ERBB2—peripheral nervous system neoplasm	2.5e-05	0.000222	CbGpPWpGaD
Thalidomide—Nausea—Doxorubicin—peripheral nervous system neoplasm	2.49e-05	7.53e-05	CcSEcCtD
Thalidomide—PTGS2—Disease—SLC2A1—peripheral nervous system neoplasm	2.46e-05	0.000218	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ENO2—peripheral nervous system neoplasm	2.41e-05	0.000214	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	2.41e-05	0.000214	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ENO2—peripheral nervous system neoplasm	2.41e-05	0.000213	CbGpPWpGaD
Thalidomide—FGFR2—brainstem—peripheral nervous system neoplasm	2.4e-05	0.0701	CbGeAlD
Thalidomide—NFKB1—Innate Immune System—HRAS—peripheral nervous system neoplasm	2.39e-05	0.000212	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.39e-05	0.000212	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	2.39e-05	0.000212	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ERBB2—peripheral nervous system neoplasm	2.38e-05	0.00021	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	2.3e-05	0.000204	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	2.29e-05	0.000203	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ENO2—peripheral nervous system neoplasm	2.27e-05	0.000201	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HRAS—peripheral nervous system neoplasm	2.27e-05	0.000201	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	2.21e-05	0.000196	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ERBB2—peripheral nervous system neoplasm	2.19e-05	0.000194	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	2.18e-05	0.000193	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—BCHE—peripheral nervous system neoplasm	2.16e-05	0.000192	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—AKT1—peripheral nervous system neoplasm	2.11e-05	0.000187	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GNAS—peripheral nervous system neoplasm	2.09e-05	0.000185	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.06e-05	0.000183	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HRAS—peripheral nervous system neoplasm	2.06e-05	0.000183	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ABCB1—peripheral nervous system neoplasm	2.05e-05	0.000182	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.05e-05	0.000181	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—BCHE—peripheral nervous system neoplasm	2.04e-05	0.00018	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TH—peripheral nervous system neoplasm	2.03e-05	0.00018	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—BCHE—peripheral nervous system neoplasm	2.03e-05	0.00018	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	2.03e-05	0.00018	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—AKT1—peripheral nervous system neoplasm	2e-05	0.000178	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.94e-05	0.000172	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.94e-05	0.000172	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.94e-05	0.000172	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.92e-05	0.000171	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—BCHE—peripheral nervous system neoplasm	1.92e-05	0.00017	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TH—peripheral nervous system neoplasm	1.92e-05	0.00017	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TH—peripheral nervous system neoplasm	1.91e-05	0.000169	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—NRAS—peripheral nervous system neoplasm	1.9e-05	0.000169	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	1.86e-05	0.000165	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.83e-05	0.000162	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—AKT1—peripheral nervous system neoplasm	1.82e-05	0.000161	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NRAS—peripheral nervous system neoplasm	1.81e-05	0.00016	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TH—peripheral nervous system neoplasm	1.81e-05	0.00016	CbGpPWpGaD
Thalidomide—PTGS1—ganglion—peripheral nervous system neoplasm	1.76e-05	0.0513	CbGeAlD
Thalidomide—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	1.7e-05	0.00015	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NRAS—peripheral nervous system neoplasm	1.67e-05	0.000148	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GNAS—peripheral nervous system neoplasm	1.66e-05	0.000147	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.63e-05	0.000144	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.62e-05	0.000143	CbGpPWpGaD
Thalidomide—NFKB1—cerebellum—peripheral nervous system neoplasm	1.58e-05	0.046	CbGeAlD
Thalidomide—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	1.57e-05	0.000139	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GNAS—peripheral nervous system neoplasm	1.56e-05	0.000139	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	1.56e-05	0.000138	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MYC—peripheral nervous system neoplasm	1.55e-05	0.000138	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.54e-05	0.000136	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ABCB1—peripheral nervous system neoplasm	1.53e-05	0.000136	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	1.53e-05	0.000136	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.5e-05	0.000133	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	1.48e-05	0.000131	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GNAS—peripheral nervous system neoplasm	1.47e-05	0.000131	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.47e-05	0.00013	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	1.45e-05	0.000128	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ABCB1—peripheral nervous system neoplasm	1.45e-05	0.000128	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	1.43e-05	0.000127	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.39e-05	0.000124	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—peripheral nervous system neoplasm	1.39e-05	0.000123	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PTPN11—peripheral nervous system neoplasm	1.38e-05	0.000122	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.37e-05	0.000121	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	1.35e-05	0.000119	CbGpPWpGaD
Thalidomide—CRBN—cerebellum—peripheral nervous system neoplasm	1.32e-05	0.0386	CbGeAlD
Thalidomide—FGFR2—Immune System—HRAS—peripheral nervous system neoplasm	1.32e-05	0.000117	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.23e-05	0.000109	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—peripheral nervous system neoplasm	1.23e-05	0.000109	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	1.22e-05	0.000109	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—peripheral nervous system neoplasm	1.22e-05	0.000108	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	1.21e-05	0.000107	CbGpPWpGaD
Thalidomide—FGFR2—cerebellum—peripheral nervous system neoplasm	1.18e-05	0.0346	CbGeAlD
Thalidomide—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	1.18e-05	0.000105	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.17e-05	0.000104	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.17e-05	0.000104	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—peripheral nervous system neoplasm	1.17e-05	0.000103	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	1.15e-05	0.000102	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.15e-05	0.000102	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	1.1e-05	9.75e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB2—peripheral nervous system neoplasm	1.09e-05	9.65e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.09e-05	9.64e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	1.08e-05	9.56e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—peripheral nervous system neoplasm	1.08e-05	9.55e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.42e-06	8.35e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	9.4e-06	8.33e-05	CbGpPWpGaD
Thalidomide—CYP1A1—parotid gland—peripheral nervous system neoplasm	9.27e-06	0.027	CbGeAlD
Thalidomide—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	9.22e-06	8.17e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.01e-06	7.98e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.94e-06	7.92e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.55e-06	7.57e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NRAS—peripheral nervous system neoplasm	8.29e-06	7.34e-05	CbGpPWpGaD
Thalidomide—PTGS2—trigeminal ganglion—peripheral nervous system neoplasm	8.25e-06	0.0241	CbGeAlD
Thalidomide—NFKB1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.96e-06	7.05e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—peripheral nervous system neoplasm	7.72e-06	6.84e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.55e-06	6.69e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—peripheral nervous system neoplasm	6.06e-06	5.37e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—peripheral nervous system neoplasm	5.65e-06	5e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—peripheral nervous system neoplasm	5.35e-06	4.74e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—peripheral nervous system neoplasm	4.48e-06	3.97e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—peripheral nervous system neoplasm	4.22e-06	3.74e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	4.21e-06	3.73e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—peripheral nervous system neoplasm	3.98e-06	3.53e-05	CbGpPWpGaD
Thalidomide—CYP2E1—cerebellum—peripheral nervous system neoplasm	3.91e-06	0.0114	CbGeAlD
Thalidomide—PTGS2—cerebellum—peripheral nervous system neoplasm	3.6e-06	0.0105	CbGeAlD
Thalidomide—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	3.26e-06	2.88e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	2.97e-06	2.63e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	2.54e-06	2.25e-05	CbGpPWpGaD
